Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment

作者
Erik Stenberg,Erik B. Näslund
出处
期刊:International Journal of Obesity [Springer Nature]
卷期号:47 (4): 251-256 被引量:41
标识
DOI:10.1038/s41366-023-01254-z
摘要

BACKGROUND: Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in patients with severe obesity and type-2 diabetes (T2D). The aim of the present study was to assess the impact of MBS on major cardiovascular adverse events (MACE) in patients with severe obesity and T2D compared to patients with T2D treated with GLP-1 RA. SUBJECTS AND METHODS: In this propensity score matched cohort study on nationwide data, patients with T2D and severe obesity who underwent MBS in Sweden from 2007 until 2019 were identified from the Scandinavian Obesity Surgery Registry and matched to a non-surgical group with T2D treated with GLP-1 RA (81.7% liraglutide, 9.0% dulaglutide, 6.0% exenatide, 1.6% lixisenatide and 0.8% semaglutide) from the general population using generalized linear model. Major outcome was MACE (hospitalization for acute coronary syndrome or cerebrovascular event or all-cause death), evaluated with multivariable Cox regression. RESULTS: In total 2161 patients (obesity class I (10.2%), class II (40.3%), class III (49.5%)) were matched to 2161 non-surgical patients (mean age 51.1 ± 9.29 vs 51.5 ± 8.92 years, 64.8% vs. 64.4% women, with mean number of diabetes drugs of 2.5 ± 0.89 vs 2.6 ± 0.87, a mean duration of diabetes of 6.0 ± 4.15 vs 6.0 ± 4.51 years with 44.2% vs. 42.8% being treated with insulin at baseline). During the study period, 113 patients (8-year cumulative incidence 9.3%) compared to 130 non-surgical patients (8-year cumulative incidence 11.3%) suffered from MACE or all-cause mortality (HR 0.76, 95%CI 0.59-0.98), and 69 patients (8-year cumulative incidence 5.1%) compared to 92 non-surgical patients (8-year cumulative incidence 7.6%) suffered from a non-fatal MACE (HR 0.68, 95%CI 0.49-0.93). CONCLUSION: In this matched cohort study, MBS was associated with lower risk for MACE compared to treatment with early GLP-1 RA in patients with T2D.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
香蕉觅云的应助被cola采纳,获得10
1秒前
月下思文完成签到 ,获得积分10
1秒前
kmkz发布了新的文献求助10
2秒前
2秒前
科研通AI6.4的应助被xpxpxpx采纳,获得10
2秒前
2秒前
善良丑完成签到 ,获得积分10
2秒前
3秒前
KeiQ完成签到,获得积分10
3秒前
小白鼠完成签到,获得积分10
3秒前
4秒前
zhenghua发布了新的文献求助10
5秒前
5秒前
5秒前
个性的小笼包完成签到,获得积分10
5秒前
Feng发布了新的文献求助10
5秒前
CC完成签到,获得积分10
6秒前
勤奋一一的应助被白英采纳,获得10
6秒前
7秒前
www发布了新的文献求助10
7秒前
7秒前
Since_2026完成签到,获得积分10
7秒前
bbabb完成签到 ,获得积分10
7秒前
小张困困发布了新的文献求助10
8秒前
学者11111发布了新的文献求助30
9秒前
困困困发布了新的文献求助10
9秒前
好好完成签到,获得积分10
9秒前
大头陈发布了新的文献求助10
9秒前
CipherSage的应助被Feng采纳,获得10
9秒前
tong完成签到,获得积分20
10秒前
10秒前
nnn发布了新的文献求助30
11秒前
123456hhh完成签到,获得积分10
11秒前
hzymed发布了新的文献求助10
11秒前
我是老大的应助被Su采纳,获得10
11秒前
12秒前
顾矜的应助被www采纳,获得10
13秒前
zhenghua完成签到,获得积分10
14秒前
诚心千青发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463